{
  "meta": {
    "title": "Recent_Updates_Mini_Test_-_Tmt",
    "url": "https://brainandscalpel.vercel.app/recent-updates-mini-test-tmt-48f2a269.html",
    "scrapedAt": "2025-11-30T12:46:37.207Z"
  },
  "questions": [
    {
      "text": "About incentives in NTEP, which of the following statements are true?<div class='question-desc-html'><ol>\n<li>500 rupees monthly(treatment months) for nutritional supplementation.</li>\n<li>Food baskets are provided yearly to TB patients.</li>\n<li>500 rupees is provided for every case notification.</li>\n<li>2500 rupees is given after successful treatment of MDR-TB to the treatment provider.</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "2 Only"
        },
        {
          "id": 2,
          "text": "1, 2, 3"
        },
        {
          "id": 3,
          "text": "1, 3"
        },
        {
          "id": 4,
          "text": "1, 3, 4"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>True</strong> statements about <strong>NTEP incentives</strong> are:</p>\n<p><strong>1. 500 rupees are monthly for nutritional supplementation.</strong></p>\n<p><strong>3. 500 rupees are provided for every case notification.</strong></p>\n<p><strong>NTEP(National Tuberculosis Elimination Program)</strong> is run by the Government of India <strong>to combat and reduce </strong>the disease burden caused by <strong>Tuberculosis</strong> <strong>in India</strong>. It is based on four strategic pillars of \"<strong>Detect - Treat - Prevent - Build</strong>\". Under the umbrella of NTEP, various schemes provide incentives and financial benefits to patients as well as health workers.</p>\n<p>Under <strong>Nikshay Poshan Yojana</strong>, a financial <strong>incentive of Rs.500/- per month</strong> is provided for nutritional support to <strong>each notified TB patient </strong>for the duration for which the patient is on anti-TB treatment.</p>\n<p>Under the <strong>TB Mukt Bharat Abhiyan</strong>, <strong>monthly food baskets</strong> are provided to <strong>patients suffering from TB</strong>. These methods are aimed to reduce the out-of-pocket expenditure of patients with TB.</p>\n<p>Also <strong>under</strong> <strong>Nikshay, Rupees 500</strong> are provided to <strong>health workers and private practitioners</strong> for <strong>notifying</strong> about a confirmed TB case. The guideline for <strong>TB notification</strong> under the <strong>NTEP</strong> is within <strong>30 days (a month)</strong> of receiving a new case. The notification must be done to the <strong>District Health Officer </strong>or<strong> the Chief Medical Officer</strong> of a District Hospital by the practitioner who diagnosed it.</p>\n<p>Also under the<strong> Direct Transfer Benefit scheme of Nikshay</strong> on successful completion of treatment, treatment providers are given <strong>2000 rupees</strong> for <strong>treating drug-sensitive, </strong>and<strong> 5000 rupees </strong>for treating <strong>drug-resistant TB.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9823",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following statements are true regarding the WHO Next Generation Partograph?<div class='question-desc-html'><ol>\n<li>The plotting begins from the latent phase of labour</li>\n<li>The active phase begins from 5cm of cervical dilatation</li>\n<li>Alert line and action line are present for guidance</li>\n<li>The second stage of labour is also plotted</li>\n<li>It is to be used in all levels of healthcare facilities</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1,3,4,5"
        },
        {
          "id": 2,
          "text": "1,2,4,5"
        },
        {
          "id": 3,
          "text": "1,2,3"
        },
        {
          "id": 4,
          "text": "2,4,5"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>True </strong>statements about the <strong>WHO Next Generation Partograph/WHO Labour Care Guide</strong> are:</p>\n<p>2.)The active phase begins from 5cm of cervical dilatation</p>\n<p>4.)The second stage of labour is also plotted</p>\n<p>5.)It is to be used in all levels of healthcare</p>\n<p>WHO Labour Care Guide is the labour monitoring tool that includes new recommendations from the WHO based on emerging evidence on normal labour progression. The new <strong>WHO Next Generation Partograph</strong>(2020) differs from the previous <strong>WHO-modified partograph(2000) </strong>in the following aspects:</p>\n<p>a.)Documentation of labour progression starts only in the <strong>active</strong> stage and begins from <strong>5 cm</strong> of cervical dilatation.</p>\n<p>b.)<strong>No action and alert lines</strong>. Rather it has time-based cut-offs for each centimetre of cervical dilatation to guide the obstetrician to take action.</p>\n<p>c.)Monitoring of the <strong>second stage of labour</strong> is included.</p>\n<p>d.)Addition of a section on <strong>supportive care</strong> of the mother- labour companionship, pain relief, oral fluid intake and posture.</p>\n<p>e.)<strong>Strength of</strong> Uterine <strong>contraction</strong> is <strong>not recorded</strong>, only frequency and duration of the contraction are noted.</p>\n<p>The <strong>WHO labour care guide</strong> is to be implemented in <strong>all levels of health care(</strong>primary, secondary and tertiary) and is to be implemented globally(but especially in resource-limited countries). <span>It includes assessments and observations that are essential for the care of <strong>all pregnant women, regardless of their risk status.</strong></span></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/bed66248c3fc43d782052756d085c0ebx724x1024.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Partograph</h3><p><strong>Partograph types:</strong></p>\n<p><strong>WHO Modified Partograph (2000)</strong></p>\n<ul>\n<li>No latent phase</li>\n<li><strong>Vaginal examination:</strong>&nbsp;This should be done no less than every 4 hours to assess cervical dilatation, descent of the fetal head, and moulding of skull bones. More frequent examination is only undertaken if indicated.</li>\n<li>Charting&nbsp;<strong>starts at 4 cm of cervical dilation.</strong></li>\n<li>Colour of liquor mentioned as C-clear, B-blood stained, M-meconium stained.</li>\n<li><strong>Moulding</strong> mentioned:\n<ul>\n<li>bones are separated and sutures can be easily felt - (0)</li>\n<li>bones touching (1+)</li>\n<li>bones overlapping but can be reduced(2+)</li>\n<li>bones severely overlapping and irreducible ( 3+).</li>\n</ul>\n</li>\n<li><strong>Alert line</strong> reflects the average rate of cervical dilation of the slowest quintile of term primigravidas, if dilation slows or ceases, the partograph plot will cross the alert line.</li>\n<li>Alert line: at 4 cm dilation and expected dilation of 1 cm/hour.</li>\n<li><strong>Action line</strong> is 2&ndash;4 hours after the alert line, which prompts interventions to accelerate labor or perform cesarean delivery.</li>\n<li>Higher rates of perinatal mortality are associated with delays of 4 hours or more after the alert line.</li>\n<li>Contractions measured for a span of 10 min (duration noted) and measured&nbsp;every 30 min (<strong>1 square = half hour</strong>).</li>\n<li>Pulse: record every 30 minutes and mark with a dot (&bull;).</li>\n<li>Blood pressure: record every 4 hours and mark with arrows, unless the patient has a hypertensive disorder or pre-eclampsia, in which case record every 30 minutes.</li>\n<li>Temperature: record every 4 hours.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/668a578db69948b98ceeb43a1a14daaex1280x2046.JPEG\" alt=\"Pearl Image\"><p><strong>WHO Composite Partograph</strong>: It is same as modified except for it has latent phase and charting done at 3 cm.</p>\n<p><strong>WHO Simplified Partograph</strong>: WHO further modified the partograph for use by skilled attendants in health centers. This simplified partograph is&nbsp;<strong>colour coded</strong>.</p>\n<ul>\n<li>The<strong>&nbsp;area to the left of the alert line</strong>&nbsp;in the cervicograph is coloured&nbsp;<strong>green</strong>, representing&nbsp;<strong>normal progress</strong>.</li>\n<li>The&nbsp;<strong>area to the right of the action line</strong>&nbsp;is coloured&nbsp;<strong>red</strong>, indicating dangerously&nbsp;<strong>slow progress</strong>&nbsp;in labour.</li>\n<li>The&nbsp;<strong>area in between the alert and action line</strong>&nbsp;is coloured&nbsp;<strong>amber</strong>, indicating the need for greater vigilance.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/4342f91530874147996cc99688c570dbx1280x1108.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9818",
      "difficulty": "hard"
    },
    {
      "text": "All of the following are indications of Retrograde intrarenal surgery to remove renal stones except?",
      "choices": [
        {
          "id": 1,
          "text": "Renal stone <2cm"
        },
        {
          "id": 2,
          "text": "Upper pole calculi"
        },
        {
          "id": 3,
          "text": "Obese patient"
        },
        {
          "id": 4,
          "text": "History of bleeding diathesis"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Lower pole calculi </strong>and not of the Upper pole <strong>is an indication to perform RIRS</strong>(<strong>Retrograde intrarenal surgery</strong>).</p>\n<p><strong>RIRS</strong> is an <strong>endoscopic</strong> approach for <strong>managing renal stones</strong>. A slimmer and more flexible URS(Ureterorenoscopes) with an active defection of the tip and <strong>laser technology </strong>is used to perform RIRS. The scope has thinner fibres which allow <strong>for retrograde access</strong> to the <strong>kidney via the ureteric orifice.</strong> Thus it provides as an</p>\n<p><strong>Indications</strong> for <strong>Retrograde intrarenal surgery </strong>(RIRS) are:</p>\n<ul>\n<li>&nbsp;Renal stones &lt;2 cm.</li>\n<li>Lower pole calculi.</li>\n<li>Obesity</li>\n<li>Musculoskeletal deformities (e.g. kyphoscoliosis) and renal anomalies (horseshoe kidney or pelvic kidney).</li>\n<li>Bleeding diathesis.&nbsp;</li>\n</ul>\n<p><strong>RIRS</strong> <strong>avoids</strong> the <strong>morbidity</strong> associated <strong>with percutaneous nephrolithotomy (PCNL)</strong>. Laser is used as an energy source for stone fragmentation. URS and RIRS can also be used in patients with bleeding disorders, as they are <strong>less invasive than PCNL</strong>. <strong>Complications</strong> include <strong>ureteric perforation </strong>and<strong> avulsion </strong>although they occur less frequently with highly flexible scopes.</p>\n<p>&nbsp;</p>\n<p>&nbsp;</p><hr><h3>Related Pearl: Management of renal and ureteric calculi</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/4cfbb28a9c864211aae21deaebd2fc99x1280x2912.JPEG\" alt=\"Pearl Image\"><p>ESWL: Extracorporeal Shock Wave Lithotripsy</p>\n<p>PCNL:&nbsp;Percutaneous nephrolithotomy</p>\n<p>URS: Ureteroscopic retrieval of stones</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9845",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following parameters are included in the Eckardt score for achalasia?<div class='question-desc-html'><ol>\n<li>Weight Loss</li>\n<li>Dysphagia</li>\n<li>Abdominal pain</li>\n<li>Regurgitation</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "2,3,4"
        },
        {
          "id": 2,
          "text": "1,3,4"
        },
        {
          "id": 3,
          "text": "1,2,4"
        },
        {
          "id": 4,
          "text": "1,2,3"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The <strong>Achalasia-Eckardt score</strong> includes <strong>4</strong> <strong>parameters</strong>. They are <strong>weight loss, dysphagia, Retrosternal pain </strong>and<strong> Regurgitation</strong>. <strong>Abdominal</strong> pain is <strong>not a part</strong> of the scoring.</p>\n<p>Achalasia is a primary oesophagal motility disorder. It is characterized by the <strong>absence</strong> of oesophagal<strong> peristalsis</strong> and <strong>impaired lower oesophagal sphincter (LES) relaxation </strong>in response to swallowing. </p>\n<p>It presents with a characteristic <strong>triad</strong> of Dysphagia, Regurgitation and Weight loss. On the barium swallow, the <strong>bird's beak appearance</strong> of the oesophagus is seen in Achalasia. <strong>Esophageal manometry</strong> is the \"gold standard\" investigation for diagnosis. The manometry findings seen in Achalasia are <strong>impaired LES relaxation</strong> and <strong>absent peristalsis </strong>with <strong>elevated LES pressure. </strong>Endoscopy and biopsy are usually carried out to rule out cancer.</p>\n<p>The ‘<strong>Eckardt score</strong>’ has been developed <strong>to assess the severity </strong>of symptoms and<strong> monitor outcomes </strong>in patients with Achalasia.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Score</strong></td>\n<td><strong>Weight loss(in kgs)</strong></td>\n<td><strong>Dysphagia </strong></td>\n<td><strong>Retrosternal pain</strong></td>\n<td><strong>Regurgitation</strong></td>\n</tr>\n<tr>\n<td><strong>0</strong></td>\n<td>None</td>\n<td>None</td>\n<td>None</td>\n<td>None</td>\n</tr>\n<tr>\n<td><strong>1</strong></td>\n<td>&lt;5</td>\n<td>Occasionally</td>\n<td>Occasionally</td>\n<td>Occasionally</td>\n</tr>\n<tr>\n<td><strong>2</strong></td>\n<td>5-10</td>\n<td>Daily</td>\n<td>Daily</td>\n<td>Daily</td>\n</tr>\n<tr>\n<td><strong>3</strong></td>\n<td>&gt;10</td>\n<td>Each meal</td>\n<td>Each meal </td>\n<td>Each meal</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>A <strong>higher score</strong> translates to <strong>severe disease</strong>.</p>\n<p><strong>Achalasia management</strong> can be medical, including <strong>sublingual nitroglycerin, nitrates or calcium channel blockers.</strong> But medical management has a limited role in the treatment and surgical intervention is sooner or later needed. <strong>Laparoscopic myotomy, pneumatic balloon dilatation and POEM(Peroral endoscopic myotomy) </strong>are effective treatments for achalasia.</p>\n<p> </p>\n<p>The image below shows the <strong>Bird's beak appearance</strong> of the oesophagus on the barium swallow.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3c63c94d7ab9479d8f8b01ec64882fffx513x962.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Barium swallow</h3><p><strong>Diffuse esophageal spasm</strong>: Corkscrew appearance</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d8236260ddee416fbac986f814ef6970x720x938.JPEG\" alt=\"Pearl Image\"><p><strong>Feline esophagus</strong>: Transient transverse bands seen in the mid and lower esophagus on a double-contrast barium swallow. It is seen in active gastroesophageal reflux, hiatus hernia, and eosinophilic esophagitis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/270761a611f6405a961fcecfe050e5edx720x1107.PNG\" alt=\"Pearl Image\"><p><strong>Achalasia</strong>: Dilated esophagus with a retained column of barium and bird beak sign.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/9d0869506ae542e1bb72aa5e0c3cc94cx245x520.JPEG\" alt=\"Pearl Image\"><p><strong>Zenker's diverticulum: </strong>Posterior outpouching of the hypopharynx through a weakness in the muscle layer called Killian dehiscence.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/35c984e64ee642878526077ceef5e961x1080x1503.JPEG\" alt=\"Pearl Image\"><p><strong>Esophageal carcinoma</strong>: Irregular narrowing, mucosal destruction, and shouldered margins.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/9c598150228f4315b254e5ba8af9b13fx1071x1024.JPEG\" alt=\"Pearl Image\"><p><strong>Schatzki's ring</strong>: Thin submucosal circumferential ring in the lower esophagus at the squamocolumnar junction.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f58822b0b33945d69d9a97c60e34bc24x720x996.JPEG\" alt=\"Pearl Image\"><p><strong>Esophageal web</strong> in a patient with Plummer Vinson syndrome. Esophageal webs are thin membranes of normal esophageal tissue consisting of mucosa and submucosa. Translucent part denotes esophageal web.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b37419089d4840df98207a1eaa0b6781x720x1339.JPEG\" alt=\"Pearl Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d9fbe2bf49d9490a91f5525c33acbb34x592x571.JPEG\" alt=\"Pearl Image\"><p><strong>Esophageal leiomyoma</strong>&nbsp;is the <strong>most common</strong>&nbsp;benign tumor of the esophagus. On barium swallow, it is seen as a discrete ovoid mass that is well outlined by barium (smooth submucosal mass). Its borders form slightly obtuse angles with the esophagal wall.</p>\n<p>The image below depicts a barium study showing the classic<strong> semilunar filling defect</strong>.&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/cc584152656442f6bcbb0fb47e97fc92x388x385.PNG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9813",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not true about the modified Duke criteria for a definitive diagnosis of infective endocarditis?",
      "choices": [
        {
          "id": 1,
          "text": "Presence of single pathological criteria is definitive of infective endocarditis"
        },
        {
          "id": 2,
          "text": "Fever >38.0°C (>100.4°F) is a minor criteria"
        },
        {
          "id": 3,
          "text": "The diagnosis of endocarditis is rejected if an alternative diagnosis is established"
        },
        {
          "id": 4,
          "text": "Presence of 1 major + 2 minor is definitive endocarditis in clinical criteria"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>If clinical criteria are used, definitive endocarditis is defined by the presence of <strong>2 major </strong>(or) <strong>1 major + 3 minor </strong>(or) <strong>5 minor criteria.</strong></p><hr><h3>Related Pearl: Modified Duke's criteria for diagnosis of infective endocarditis</h3><div class=\"page\" title=\"Page 2415\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Diagnosis of Infective endocarditis is by Duke's Criteria, which requires either:</p>\n</div>\n</div>\n</div>\n</div>\n<ol>\n<li>Pathologic criteria</li>\n<li>Clinical criteria</li>\n</ol>\n<p>If clinical criteria are used, definitive endocarditis is defined by the presence of&nbsp;<strong>2 major </strong>or&nbsp;<strong>1 major + 3 minor </strong>or&nbsp;<strong>5 minor criteria.</strong></p>\n<p>The presence of single pathological criteria is definitive of infective endocarditis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/186ed21749ed4d3ab7e43344abb39a78x1200x2770.JPEG\" alt=\"Pearl Image\"><p>Note:&nbsp;The diagnosis of endocarditis is rejected if an alternative diagnosis is established either when:</p>\n<ul class=\"p-rich_text_list p-rich_text_list__bullet\" data-stringify-type=\"unordered-list\" data-indent=\"0\" data-border=\"0\">\n<li data-stringify-indent=\"0\" data-stringify-border=\"0\">Symptoms resolve and do not recur with &lt;4 days of antibiotic therapy OR</li>\n<li data-stringify-indent=\"0\" data-stringify-border=\"0\">If surgery or autopsy yields no pathologic or macroscopic evidence of endocarditis in &lt;4 days of antimicrobial therapy.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3953",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following statements are true regarding TB drug resistance?<div class='question-desc-html'><ol>\n<li>RR TB should be proven to be sensitive to Isoniazid. </li>\n<li>MDR-TB implies resistance to Isoniazid and Rifampicin</li>\n<li>Pre-XDR-TB is MDR-TB plus resistance to at least one group A drug(Bedaquilline or Linezolid)</li>\n<li>XDR-TB is resistant to all current medications available for the treatment of TB.</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1,2,3,4"
        },
        {
          "id": 2,
          "text": "2,3"
        },
        {
          "id": 3,
          "text": "2 Only"
        },
        {
          "id": 4,
          "text": "1 only"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>True</strong> statements is&nbsp;<strong>MDR-TB implies resistance to Isoniazid and Rifampicin.</strong></p>\n<p>The <strong>NTEP</strong> classifies drug resistance patterns for TB into <strong>5&nbsp;groups:</strong>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td rowspan=\"2\"><strong>Types of Drug Resistance TB (DR TB)</strong></td>\n<td colspan=\"4\" rowspan=\"1\"><strong>Resistant to</strong></td>\n</tr>\n<tr>\n<td><strong>Isoniazid (H)</strong></td>\n<td><strong>Rifampicin (R)</strong></td>\n<td><strong>Fluroquinolones (FQ) =&nbsp;</strong><br /><strong>Ofloxacin,&nbsp;Levofloxacin,&nbsp;</strong><br /><strong>Moxifloxacin</strong></td>\n<td><strong>Group A Drugs =&nbsp;</strong><br /><strong>Bedaquiline/&nbsp;Linezolid</strong></td>\n</tr>\n<tr>\n<td>H Mono / Poly Drug Resistance</td>\n<td><strong>Resistant</strong></td>\n<td><strong>Sensitive</strong></td>\n<td><strong>Unknown/ Sensitive</strong></td>\n<td><strong>Unknown/ Sensitive</strong></td>\n</tr>\n<tr>\n<td>Rifampicin Resistance (RR)</td>\n<td><strong>Unknown/ Sensitive</strong></td>\n<td><strong>Resistant</strong></td>\n<td><strong>Unknown/ Sensitive</strong></td>\n<td><strong>Unknown/ Sensitive</strong></td>\n</tr>\n<tr>\n<td>Multi Drug Resistance TB (MDR TB</td>\n<td><strong>Resistant</strong></td>\n<td><strong>Resistant</strong></td>\n<td><strong>Unknown/ Sensitive</strong></td>\n<td><strong>Unknown/ Sensitive</strong></td>\n</tr>\n<tr>\n<td>Pre-Extensive Drug Resistance (Pre -XDR)</td>\n<td><strong>Resistant</strong></td>\n<td><strong>Resistant</strong></td>\n<td><strong>Resistant</strong></td>\n<td><strong>Unknown/ Sensitive</strong></td>\n</tr>\n<tr>\n<td>Extensive Drug Resistance (XDR)</td>\n<td><strong>Resistant</strong></td>\n<td><strong>Resistant</strong></td>\n<td><strong>Resistant</strong></td>\n<td><strong>Resistant</strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: ATT Regimen for TB Patients</h3><p>As per the latest recommendations from <strong>National Tuberculosis Elimination Programme (NTEP)</strong>, treatment of TB is now based primarily on <strong>drug susceptibility testing</strong>. This is irrespective of new cases, previously treated cases or recurrent TB cases. <br />All cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (<strong>No classification into category I or II</strong>)</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months H R Z E</td>\n<td>4 months H R E</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2><strong><span>Classification based on drug resistance. </span></strong></h2>\n<p><span>The<strong> </strong>cases are classified as:</span></p>\n<ul>\n<li><strong>Mono-resistant (MR):</strong> A TB patient, who is resistant to one 1st line anti-TB drug only.</li>\n<li><strong>Poly-Drug Resistant (PDR):</strong> A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. </li>\n<li><strong>Rifampicin Resistant (RR):</strong> A TB patient, who is resistant to <strong>rifampicin</strong> with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.</li>\n<li><strong>Multi-Drug Resistant (MDR):</strong> A TB patient, who is resistant to <strong>both isoniazid and rifampicin.</strong></li>\n<li><strong>Extensively Drug-Resistant (XDR):</strong> A MDR TB patient who is additionally resistant to a <strong>fluoroquinolone</strong> (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)</li>\n</ul>\n<h2><strong><span>Standard DR TB regimen</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<h2> </h2>\n<h2><strong><span>Criteria for patients to receive standard Drug Resistant TB regimen:</span></strong></h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> or <strong>pre-XDR-TB</strong> ( MDR/RR-TB and resistance to fluoroquinolones). </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br /></strong></li>\n</ol>\n</td>\n<td>Pregnant and lactating women</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Legend</p>\n<p>FQ: Fluoroquinolone</p>\n<p>SLI: Second Line Injectable</p>\n<p>PLHIV: People Living with HIV</p>\n<p>Lfx: Levofloxacin</p>\n<p>Pa: Pretomanid</p>\n<p>H: Isoniazid</p>\n<p>Hh: High Dose Isoniazid</p>\n<p>R: Rifampicin</p>\n<p>E: Ethambutol</p>\n<p>Z: Pyrazinamide</p>\n<p>Mfx: Moxifloxacin</p>\n<p>Km: Kanamycin</p>\n<p>Am: Amikacin</p>\n<p>Eto: Ethionamide</p>\n<p>Cfz: Clofazimine</p>\n<p>Bdq: Bedaquiline</p>\n<p>Lzd: Linezolid</p>\n<p>Cs: Cycloserine</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9835",
      "difficulty": "medium"
    },
    {
      "text": "Match the following IT platforms with their relevant application.<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td><strong>IT- Platform:</strong></td>\n<td><strong>Used for:</strong></td>\n</tr>\n<tr>\n<td>1.) Kilkari</td>\n<td>a.) Leprosy patient monitoring</td>\n</tr>\n<tr>\n<td>2.) Mobile academy</td>\n<td>b.) TB patient monitoring</td>\n</tr>\n<tr>\n<td>3.) Nikshay</td>\n<td>c.) Pregnant women and new mothers</td>\n</tr>\n<tr>\n<td>4.) Nikusth</td>\n<td>d.) Training of ASHA</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "1-c, 2-b, 3-d, 4-a"
        },
        {
          "id": 2,
          "text": "1-a, 2-d, 3-b, 4-c"
        },
        {
          "id": 3,
          "text": "1-c, 2-d, 3-b, 4-a"
        },
        {
          "id": 4,
          "text": "1-c, 2-d, 3-a, 4-b"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The correct match is 1-c, 2-d, 3-b, 4-a:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>IT- Platform:</strong></td>\n<td><strong>Used for:</strong></td>\n</tr>\n<tr>\n<td>1.) Kilkari</td>\n<td>c.) Pregnant women and new mothers</td>\n</tr>\n<tr>\n<td>2.) Mobile academy</td>\n<td>d.) Training of ASHA</td>\n</tr>\n<tr>\n<td>3.) Nikshay</td>\n<td>b.) TB patient monitoring</td>\n</tr>\n<tr>\n<td>4.) Nikusth</td>\n<td>a.) Leprosy patient monitoring</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>\n<p><strong>Kilkari<em> </em></strong>is a new scheme under <strong>NRHM</strong>(National Rural Health Mission). It is a <strong>mobile health education service</strong> that provides <strong>pregnant</strong> women, <strong>new mothers</strong>, and their families with timely, accessible, accurate and relevant information about Reproductive, Maternal, Neonatal and Child health. <span data-preserver-spaces=\"true\">It consists of an <strong>Interactive pre-recorded Voice Response (IVR)</strong> system, which informs pregnant women about pregnancy and child health care, covering the expected events from the <strong>4th month of conception</strong> until the <strong>child is one year</strong> <strong>old</strong></span><strong><span data-preserver-spaces=\"true\">. </span></strong><span data-preserver-spaces=\"true\">Each call is for </span><strong><span data-preserver-spaces=\"true\">2 minutes </span></strong>and s<span data-preserver-spaces=\"true\">ervices are available in all states in their </span><strong><span data-preserver-spaces=\"true\">regional dialects.</span></strong></p>\n<p><strong>Mobile Academy</strong> is a <strong>Reproductive Maternal Neonatal and Child health training course </strong>designed to refresh <strong>ASHA</strong> workers’ knowledge of life-saving preventative health behaviours and improve the quality of their engagement with new and expecting mothers and their families. </p>\n<p><strong>Nikusth</strong><strong> </strong>is a real-time <strong>web-based system</strong> for data management for <strong>leprosy</strong> cases. It is software for <strong>monitoring</strong> leprosy patients,<strong> </strong>with a <strong>patient tracking mechanism</strong> launched by the Health &amp; Family Welfare Minister Government of India.</p>\n<p><strong>NIKSHAY</strong> is a web-based solution for monitoring  <strong>TB</strong> <strong>patients. </strong>(The word is a combination of two Hindi words NI and KSHAY, meaning eradication of TB).</p>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9867",
      "difficulty": "easy"
    },
    {
      "text": "Auxiliary liver transplantation is beneficial in which of the following conditions:",
      "choices": [
        {
          "id": 1,
          "text": "Acute liver failure"
        },
        {
          "id": 2,
          "text": "Hepatocellular carcinoma"
        },
        {
          "id": 3,
          "text": "Genetic Hemochromatosis"
        },
        {
          "id": 4,
          "text": "Chronic viral hepatitis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Auxiliary liver transplantation</strong> is beneficial in <strong>acute liver failure.</strong></p>\n<p>Auxiliary liver transplantation involves implanting a healthy liver graft <strong>heterotopically </strong>or<strong> orthotopically</strong> while leaving the whole or part of the native liver intact. The <strong>auxiliary partial orthotopic LT (APOLT)</strong> technique is used in patients with<strong> acute liver failure</strong> and <strong>metabolic diseases </strong>(primary hypercholesterolemia, glycogen storage disorders, organic acidemia, etc). In acute liver failure, this technique helps in native liver regeneration and <strong>immunosuppression withdrawal</strong>. In children with metabolic liver diseases, this technique helps in <strong>future gene therapy</strong>.</p>\n<p>Options B, C, and D are chronic liver diseases not suitable for auxiliary liver transplantation.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7912",
      "difficulty": "medium"
    },
    {
      "text": "A 21-year-old male patient is admitted to the emergency department due to breathlessness and hypotension after penetrating trauma to the chest. His heart sounds are muffled and the ECG findings are given below. Which of the following is not indicated in managing this patient?",
      "choices": [
        {
          "id": 1,
          "text": "I.V fluids"
        },
        {
          "id": 2,
          "text": "e-FAST"
        },
        {
          "id": 3,
          "text": "Pericardiocentesis"
        },
        {
          "id": 4,
          "text": "Left antero-lateral thoracotomy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given patient came with <strong>penetrating chest trauma </strong>and had <strong>muffled heart sounds.</strong> The ECG shows <strong>decreased voltage</strong> and <strong>electrical alternans</strong> (alternating amplitude of QRS complexes). All these features suggest the diagnosis of <strong>Cardiac Tamponade secondary to penetrating trauma</strong>. <strong>Needle Pericardiocentesis</strong> is <strong>not done</strong> for patients with Cardiac tamponade after <strong>penetrating</strong> trauma.</p>\n<p><strong>Cardiac tamponade</strong> is characterized by the accumulation of fluid in the <strong>pericardial space</strong> leading to <strong>impairment of diastolic relaxation</strong> of the cardiac chambers. This leads to a decline in cardiac output. The characteristic signs of cardiac tamponade are <strong>Beck's triad, </strong>which consists<strong> of </strong><strong>hypotension, </strong><strong>muffled heart sounds, </strong>and <strong>elevated jugular venous pressure.</strong></p>\n<p><strong>ECG</strong> shows <strong>reduced voltage </strong>and <strong>electrical alternans.</strong> Electric alternans is a specific finding caused by the anteroposterior swinging of the heart with each contraction. When the heart is nearer to the chest wall, it leads to an increased amplitude deflection on the ECG, whereas, a lower amplitude deflection is seen when the heart moves away from the chest wall.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d34269cd1a0b463dbc4794ed662ad203x1280x1090.JPEG\" alt=\"Explanation Image\"><p><strong>e-Fast</strong> is <strong>diagnostic</strong> of <strong>cardiac tamponade</strong> as it detects the free fluid in the pericardial sac. Rapid <strong>infusion of as little as 250 ml intravenous normal saline</strong> improves the cardiac haemodynamics in a significant proportion of tamponade patients. <strong>Pericardiocentesis</strong> has <strong>no role </strong>in the management of <strong>cardiac tamponade secondary to penetrating myocardial injury</strong>. It can be done for blunt trauma leading to tamponade.</p>\n<p>The correct immediate<strong> treatment o</strong>f tamponade is <strong>operative</strong>, either via a subxiphoid window or by open surgery (<strong>sternotomy or left anterolateral thoracotomy</strong>), with the repair of the heart in emergency or in OT.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/f9445de15bd442a4917eb1889cb012eb.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9849",
      "difficulty": "hard"
    },
    {
      "text": "As per the IAP standard treatment guidelines 2022, which of the following factors are considered risk factors for developing subsequent epilepsy in a child with febrile seizures?<div class='question-desc-html'><p> </p>\n<ol>\n<li>Family history of epilepsy</li>\n<li>Any neurodevelopmental problem</li>\n<li>Prolonged or focal febrile seizures</li>\n<li>Febrile status epilepticus</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "Only 1 and 3"
        },
        {
          "id": 2,
          "text": "Only 2 and 4"
        },
        {
          "id": 3,
          "text": "1,2,3,4"
        },
        {
          "id": 4,
          "text": "Only 3 and 4"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Risk factors</strong> for developing <strong>subsequent epilepsy</strong> in a child with febrile seizures include:</p>\n<ol>\n<li>Family history of epilepsy</li>\n<li>Any neurodevelopmental problem</li>\n<li>Prolonged or focal febrile seizures</li>\n<li>Febrile status epilepticus</li>\n</ol>\n<p><strong>Febrile seizures</strong> are described as seizures that occur in children of the age of <strong>6&ndash;60 months </strong>with a temperature of <strong>38&ordm;C</strong>&nbsp;(<strong>100.4&deg;F) or higher</strong>, without underlying intracranial infections or prior unprovoked seizures. <strong>Epilepsy</strong> is a disorder of the brain characterized by a predisposition to generate <strong>repeated seizures.&nbsp;</strong>Children with <strong>simple</strong> febrile seizures have a <strong>1% risk of developing epilepsy</strong> <strong>by</strong> the age of<strong> 7 years</strong> (<strong>same as the general population</strong>) and 2.4% by 25 years of age.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9880",
      "difficulty": "medium"
    },
    {
      "text": "Which is the new IAP recommendation for the first line treatment of Rickets in children?",
      "choices": [
        {
          "id": 1,
          "text": "Stoss therapy"
        },
        {
          "id": 2,
          "text": "Bolus on day 1, followed by Daily Vitamin D supplementation"
        },
        {
          "id": 3,
          "text": "Daily treatment with Vitamin D"
        },
        {
          "id": 4,
          "text": "Alternate day Vitamin D supplementation"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The <strong>IAP(Indian Academy of Pediatrics)</strong> now recommends <strong>daily&nbsp; Vitamin D as the first line of treatment </strong>in children with <strong>rickets</strong>.</p>\n<p>A deficiency of vitamin D results in poor mineralization of the bone, leading to <strong>rickets in childre</strong>n. Rickets presents with&nbsp;skeletal changes&nbsp;like&nbsp;bowing of legs&nbsp;and&nbsp;bone pain once the child starts to walk. Prominent costochondral joints (<strong>rachitic rosary</strong>), craniotabes, scoliosis, fractures, dental anomalies and alopecia may also be seen. <strong>Radiological features</strong>&nbsp;show&nbsp;<strong>cupping at metaphyses</strong>,&nbsp;<strong>fraying</strong>, and&nbsp;<strong>widening of the growth plate</strong>.</p>\n<p><strong>IAP</strong> has updated the <strong>treatment guidelines</strong> for children with <strong>rickets</strong>:</p>\n<p><strong>Daily treatment </strong>with <strong>oral</strong> <strong>Vitamin</strong> <strong>D</strong> preparations is recommended, as daily supplementation is more physiological. The duration of treatment is <strong>at least 12 weeks.</strong> Vitamin D dosage is <strong>2000 I.U in infants </strong>and <strong>3000 I.U in children over one year of age</strong>. <strong>Calcium</strong> <strong>intake of 50-75 mg/kg/day </strong>(not exceeding 500 mg/day) must be ensured through diet or supplementation with vitamin D. <strong>Monitoring</strong> during treatment is done with <strong>radiographs</strong> and lab values of <strong>Serum calcium, phosphate, alkaline phosphatase and serum 25 (OH)D levels.</strong></p>\n<p><strong>Stoss therapy</strong> was earlier used for treating Vitamin D deficiency. Here,&nbsp;<strong>300,000-600,000 IU</strong> of vitamin D was administered orally or intramuscularly in 2 or 4 doses <strong>over 1 day</strong>.</p><hr><h3>Related Pearl: Radiological Features of Rickets</h3><p>Radiological features of rickets:</p>\n<ul>\n<li><strong>Loss of provisional zone of calcification: </strong>earliest radiological finding of rickets. </li>\n<li>Delayed appearance of the epiphysis</li>\n<li><strong>Widening of growth plate: </strong>normal width of growth plate is 2-4mm. It is increased in cases of rickets due to excessive accumulation of uncalcified osteoid at the growth plate.</li>\n<li><strong>Cupping of metaphysis: </strong>normally metaphysis meets epiphysis as a smooth line of sclerosis. But in rickets the line is absent and the metaphyseal ends appear irregular and the cartilage accumulating in the growth plate creates a depression in the metaphysis causing cupping.</li>\n<li><strong>Fraying</strong>: indistinct margins of the metaphysis</li>\n<li><strong>Bowing of diaphysis, </strong>with thinning of cortices</li>\n<li>In healing rickets, zone of calcification becomes denser. </li>\n</ul>\n<p>The above features are prominent at the growth plates where growth is greatest:</p>\n<ul>\n<li>Knee: distal femur, proximal tibia</li>\n<li>Wrist: especially the ulna</li>\n<li>Anterior rib ends: <strong>rachitic rosary</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3fb9e16daa324d32bc69ad013a616401x1280x1694.JPEG\" alt=\"Pearl Image\"><p>The below image shows bowing of legs in rickets.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2540c743846448f9a7b302483397230ax256x406.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9819",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following diseases is not included in NP-NCD?",
      "choices": [
        {
          "id": 1,
          "text": "Non alcoholic fatty liver disease"
        },
        {
          "id": 2,
          "text": "Chronic Kidney disease"
        },
        {
          "id": 3,
          "text": "Hypothyroidism"
        },
        {
          "id": 4,
          "text": "COPD"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Hypothyroidism is not included in the NP-NCD program<strong>.</strong></p>\n<p>The <strong>NPCDCS</strong> (National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke) has been <strong>changed to NP-NCD </strong>(<strong>National Program for Prevention and Control of Non-Communicable Diseases</strong>). It now includes initiatives and guidelines on the prevention and management of new diseases like:</p>\n<ul>\n<li><strong>Non-alcoholic fatty liver disease</strong></li>\n<li><strong>Chronic Kidney disease</strong></li>\n<li><strong>Asthma, COPD</strong></li>\n<li><strong>STEMI</strong></li>\n<li><strong>Stroke</strong></li>\n</ul>\n<p>It continues to<strong> include</strong> the <strong>diseases</strong> already covered in <strong>NPCDCS</strong>. For effective program management, the NCD divisions have been established at <strong>National, State, and District headquarters </strong>to ensure the activities' planning, implementation, monitoring, and evaluation.</p>\n<p>The NPCDCS program was first introduced under the NHM(National Health Mission) umbrella in 2010, to prevent screen, and treat Non-communicable diseases in India. In 2018, Non-Communicable Diseases like Cardiovascular diseases, Cancer, Chronic Respiratory Diseases, Diabetes, and other NCDs were estimated to account for 63% of all deaths, thus making them the leading causes of death. <strong>Hypothyroidism </strong>has<strong> never</strong> been a<strong> part of the program</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9828",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a component of the REDS path in the National suicide prevention strategy?",
      "choices": [
        {
          "id": 1,
          "text": "Reduce suicidal deaths by 2% in the next 5 years"
        },
        {
          "id": 2,
          "text": "Enhance health services to provide suicide prevention strategies"
        },
        {
          "id": 3,
          "text": "Develop community resilience, and societal support for suicide prevention"
        },
        {
          "id": 4,
          "text": "Strengthen surveillance and evidence generation"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The&nbsp;<strong>National Suicide Prevention Strategy (NSPS)</strong> is a multisectoral approach that will involve national and international government ministries, families and communities, and educational institutes. It aims to <strong>reduce suicide mortality by 10%</strong> in India by <strong>2030.</strong></p>\n<p>It recommends<strong> REDS </strong>path for suicide prevention.</p>\n<ul>\n<li aria-level=\"1\"><strong>R</strong>einforce leadership, partnership, and institutional capacity in the country</li>\n<li aria-level=\"1\"><strong>E</strong>nhance the health services capacity to provide suicide prevention services</li>\n<li aria-level=\"1\"><strong>D</strong>evelop community resilience, societal support for suicide prevention and reduce stigma against suicidal behaviours</li>\n<li aria-level=\"1\"><strong>S</strong>trengthen surveillance and evidence generation.&nbsp;</li>\n</ul>\n<p><strong>Objectives</strong></p>\n<ul>\n<li aria-level=\"1\">To establish<strong> effective surveillance mechanism</strong> for suicide prevention in <strong>next 3 years</strong></li>\n<li aria-level=\"1\">To establish <strong>psychiatric OPDs</strong> that provide suicide prevention services through District Mental Health Programme, within <strong>next 5 years</strong></li>\n<li aria-level=\"1\">To <strong>integrate mental well-being curriculum</strong> in all educational institutes within <strong>next 8 years</strong>.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7450",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a new drug approved by the FDA for the treatment of Rett syndrome?",
      "choices": [
        {
          "id": 1,
          "text": "Olcegepant"
        },
        {
          "id": 2,
          "text": "Lasmiditan"
        },
        {
          "id": 3,
          "text": "Trofinetide"
        },
        {
          "id": 4,
          "text": "Erenumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><span><strong>Trofinetide</strong> is the newly <strong>FDA-approved drug</strong> for the treatment of <strong>Rett syndrome.</strong></span></p>\n<p><span>The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is<strong> unknown</strong>. It is a synthetic analog of the amino‐terminal tripeptide of insulin-like growth factor (IGF-1) designed to treat the core symptoms of Rett syndrome by <strong>potentially reducing neuroinflammation and supporting synaptic function of the protein fragment glypromate (GPE).&nbsp;</strong>IGF-1 is produced by both major types of brain cells &ndash; neurons and glia; IGF-1 in the brain is critical for both normal development and response to injury and disease<strong>.&nbsp;</strong>Trofinetide has been shown to <strong>inhibit the production of inflammatory cytokines,</strong> <strong>inhibit overactivation of microglia and astrocytes</strong>, and <strong>increase the amount of available IGF-1 </strong>that can bind to IGF-1 receptors.</span></p>\n<p><span>It is<strong>&nbsp;</strong>Indicated for the treatment of <strong>Rett syndrome.</strong></span></p>\n<p><span><strong>Adverse effects</strong> include diarrhea, vomiting, fever, seizure, anxiety, decreased appetite, fatigue, nasopharyngitis</span></p>\n<p>&nbsp;</p>\n<p><span>Other options:</span></p>\n<p><span>Option A:&nbsp;<strong>Olcegepant</strong>&nbsp;is a calcitonin gene-related peptide (<strong>CGRP</strong>)&nbsp;<strong>antagonist</strong> which was considered for the treatment of&nbsp;<strong>migraine,</strong>&nbsp;but discontinued.</span></p>\n<p><span>Option B:&nbsp;<strong>Lasmiditan</strong>&nbsp;is&nbsp;</span><span>a nontriptan 5HT1F receptor&ndash;selective agonist&nbsp;</span><span>and is used to treat migraine.</span></p>\n<p><span>Option D:&nbsp;<strong>Erenumab</strong> is a&nbsp;<strong>CGRP (calcitonin gene-related peptide) blocking antibody</strong>&nbsp;used in the treatment migraine.</span>&nbsp;</p>\n<p>&nbsp;</p>\n<p>Note: The spelling of the drug in the options has been corrected from Trofin<strong data-stringify-type=\"bold\">i</strong>tide to Trofin<span><strong data-stringify-type=\"bold\">e</strong></span>tide.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9162",
      "difficulty": "medium"
    },
    {
      "text": "Open vial policy is not applicable to which of the following vaccines?",
      "choices": [
        {
          "id": 1,
          "text": "Hepatitis B"
        },
        {
          "id": 2,
          "text": "BCG"
        },
        {
          "id": 3,
          "text": "Pentavalent vaccine"
        },
        {
          "id": 4,
          "text": "Rotoviral vaccine in New container"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Open vial policy</strong> is not applicable for BCG and measles vaccines.</p>\n<p>It is <strong>applicable</strong> for:</p>\n<ul>\n<li>DPT</li>\n<li>TT</li>\n<li><strong>Hepatitis B</strong> vaccine</li>\n<li><strong>OPV</strong></li>\n<li><strong>Pentavalent</strong> vaccine</li>\n<li>Rotavirus vaccine (New version with the VVM on the side)</li>\n</ul><hr><h3>Related Pearl: Open Vial Policy</h3><p>Open vial policy allows for reuse of partially used <strong>multidose vials</strong> of applicable vaccines under the Universal Immunization Programme in subsequent sessions up to&nbsp;<strong>4&nbsp;weeks</strong> subject to certain conditions and thereby reducing vaccine wastage.</p>\n<p>It is applicable only for <strong>DPT, TT, hepatitis B vaccine, OPV, liquid pentavalent vaccine, rotavirus vaccine(new version with the VVM on the side), and JE vaccines (inactivated). </strong>It is not applicable to <strong>BCG and measles vaccines.&nbsp;</strong></p>\n<p>Vaccine vials opened in session-site can be used in more than one session up to four weeks if <strong>expiry date has not passed, if storage and transport was appropriate, no contamination has occurred in vial septum, asepsis in withdrawing was practiced and if vaccine vial monitor has not reached discard point.</strong></p>\n<p>Open vials should <strong>not</strong> be submerged in water. All open vials should have a record of&nbsp;<strong>date and time of opening</strong>. At the end of a session, all vaccines should be returned to the cold chain point and segregated as re-usable and non-reusable. All open vials of BCG, measles must be destroyed after 48 hours or before next session, whichever is earlier.</p>\n<p>In case of any <strong>adverse events following immunization</strong>, all open vials should not be discarded until investigation is complete. All vials must be transported in zipper bags in the vaccine carrier and recorded in stock register. Ice packs used should be well sealed.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA9477",
      "difficulty": "medium"
    },
    {
      "text": "A 6-month-old male child with a cough and cold for the last 7 days is taken to an ASHA worker by his mother. On examination, the child had a respiratory rate of 42 breaths/min and no chest indrawing or grunting.  What would be the next step followed by the ASHA worker?",
      "choices": [
        {
          "id": 1,
          "text": "ASHA herself advices for home-based care"
        },
        {
          "id": 2,
          "text": "ASHA  refers the child to the nearby PHC"
        },
        {
          "id": 3,
          "text": "ASHA gives the first dose of oral Amoxicillin"
        },
        {
          "id": 4,
          "text": "ASHA gives the first dose of injectable Amoxicillin and refers to District hospital"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>next best step</strong> for the <strong>ASHA</strong> worker is to <strong>herself give advice for home-based care.</strong></p>\n<p>The <strong>6-month</strong>-old child with a cough and cold for 7 days, having a <strong>respiratory rate of 42 breaths per minute</strong> and <strong>no</strong> <strong>chest indrawings </strong>or<strong> grunting</strong> is classified as <strong>\"No pneumonia\".</strong> According to the latest <strong>SAANS</strong> guidelines (<strong>Social Awareness and Actions to Neutralize Pneumonia Successfully)</strong>, for a child with No Pneumonia, an ASHA worker on her own will advise Home-based care for the child. </p>\n<p><strong>Home-based care</strong> includes:</p>\n<ul>\n<li>Exclusive breastfeeding for &lt;6 months old child as much as possible.</li>\n<li>For older children give plenty of oral fluids</li>\n<li>Home-made soothing cough remedies can be given to children more than 6 months old.</li>\n<li>Mothers should be taught about the danger signs and report to the ASHA worker or ANM if any danger signs develop.</li>\n</ul>\n<p>For classifying Pneumonia, <strong>SAANS guidelines </strong>of India are similar to the <strong>IMNCI protocols</strong> of WHO, <strong>except</strong> it <strong>allows ASHA to take the decision for advising Home based treatment</strong> as she has been trained for classifying Pneumonia. Also in the SAANS guidelines<strong> Chest indrawing is a feature of severe pneumonia, </strong>while it comes under Pneumonia in the IMNCI guidelines.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a4f8278785984aec8966e3e0b39cb7d0x1280x1813.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9862",
      "difficulty": "hard"
    },
    {
      "text": "All of the following surgical procedures can be conducted in a Primary Health Center (PHC) except _____.",
      "choices": [
        {
          "id": 1,
          "text": "Vasectomy"
        },
        {
          "id": 2,
          "text": "Cholecystectomy"
        },
        {
          "id": 3,
          "text": "Incision and drainage of abscesses"
        },
        {
          "id": 4,
          "text": "Hydrocelectomy"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Cholecystectomy is not a surgical procedure that is conducted in a PHC. The surgical&nbsp;procedures done in PHC include <strong>suturing</strong> of wounds,<strong> incision and drainage </strong>of abscesses,<strong> v</strong><strong>asectomy</strong>, <strong>tubectomy</strong>, and<strong>&nbsp;hydrocelectomy</strong>.</p>\n<p>Services provided under PHC:</p><ol>\n<li aria-level=\"1\">General services: <strong>OPD</strong>, teleconsultation services</li>\n<li aria-level=\"1\"><strong>Emergency services</strong></li>\n<li aria-level=\"1\"><strong>24x7 labor rooms</strong></li>\n<li aria-level=\"1\">Antenatal clinics, non-communicable diseases (NCD) clinics</li>\n<li aria-level=\"1\">Rotational specialist clinics</li>\n<li aria-level=\"1\">Surgical procedures:</li>\n<ul>\n<li aria-level=\"2\">Suturing of wounds</li>\n<li aria-level=\"2\"><strong>Incision and drainage of abscesses</strong></li>\n<li aria-level=\"2\"><strong>Vasectomy</strong>, tubectomy,<strong> hydrocelectomy</strong> in PHCs with a functional minor OT, and standard infection-prevention protocols</li>\n</ul>\n<li aria-level=\"1\">Antenatal care and services:</li>\n<ul>\n<li aria-level=\"2\">Detecting pregnancy&nbsp;</li>\n<li aria-level=\"2\">Provision of ANC and counseling services</li>\n<li aria-level=\"2\">Identification, management, and referral of high-risk pregnancies</li>\n<li aria-level=\"2\">Detection of alarming signs during pregnancy and labor with timely and appropriate referral</li>\n<li aria-level=\"2\">Monitoring high-risk pregnancies</li>\n<li aria-level=\"2\">Management of malaria for pregnant women, as per National Center for Vector Borne Diseases Control (NCVBDC) guidelines</li>\n<li aria-level=\"2\">Management of tuberculosis during pregnancy</li>\n<li aria-level=\"2\">Management of mild/moderate anemia</li>\n<li aria-level=\"2\">Management of gestational diabetes mellitus, as per Government of India guidelines</li>\n</ul>\n</ol>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7273",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is a false statement about the Indian Hypertension Control Initiative (IHCI)?",
      "choices": [
        {
          "id": 1,
          "text": "The IHCI monitoring personnel includes cardiovascular health officers and senior treatment supervisors"
        },
        {
          "id": 2,
          "text": "Provision of real-time blood pressure monitoring for all patients via information systems"
        },
        {
          "id": 3,
          "text": "The IHCI provides 30-day medication for individuals registered for hypertension management"
        },
        {
          "id": 4,
          "text": "The target is a 90% reduction in the prevalence of hypertension by the year 2025"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The false statement about the Indian Hypertension Control Initiative is a 90% reduction in the prevalence of hypertension by the year 2025. </p>\n<p>The IHCI is an initiative by the <strong>MoHFW, WHO, ICMR, and state governments</strong> to control hypertension in India. It has adopted the goal of <strong>“25 by 25”</strong> to <strong>reduce the prevalence of hypertension</strong> in India <strong>by 25% by 2025</strong>. The activities of IHCI are monitored by the <strong>cardiovascular health officers (CVHO's)</strong> at the state and district level and by the <strong>senior treatment supervisors (STS's)</strong> at the sub-district level. The IHCI has strengthened the prevention of hypertension by ensuring the <strong>provision of antihypertensive medications</strong> for <strong>30 days</strong> to all patients registered under the IHCI.</p>\n<p>The 5 components of IHCI are:</p>\n<ol>\n<li aria-level=\"1\">Use of <strong>standardized hypertension treatment protocols</strong> approved by national and global policies.</li>\n<li aria-level=\"1\"><strong>Availability of recommended protocol drugs</strong> to provide a regular and uninterrupted supply of medications.</li>\n<li aria-level=\"1\"><strong>Task-sharing </strong>and<strong> team-based care</strong> involving nurses, health workers, and ASHAs to improve treatment compliance.</li>\n<li aria-level=\"1\"><strong>Patient-centered services</strong> provide easy access to BP monitoring at Health &amp; wellness centers and PHCs.</li>\n<li aria-level=\"1\"><strong>Information systems</strong> that provide real-time BP monitoring to improve patient follow-ups: Use of the <strong>“Simple App”</strong> in all IHCI states.</li>\n</ol>\n<p>*Note: Amlodipine, telmisartan, and chlorthalidone are the drugs of choice in the standardized treatment protocols of the IHCI.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7860",
      "difficulty": "medium"
    },
    {
      "text": "A 46-year-old male was diagnosed with a colorectal polyp. He was operated and a sessile, hyperplastic polyp measuring 24mm in diameter was completely removed. No evidence of an invasive disease was noted. What follow-up should be advised to this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Site check after 6 months by colonoscopy"
        },
        {
          "id": 2,
          "text": "Colonoscopy after every year"
        },
        {
          "id": 3,
          "text": "One-off colonoscopy at 3 years"
        },
        {
          "id": 4,
          "text": "No further follow-up is required"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>For a <strong>sessile</strong>, <strong>hyperplastic</strong> <strong>colorectal</strong> <strong>polyp</strong> measuring <strong>24mm</strong> in diameter, <strong>follow-up</strong> is done with a <strong>one-off colonoscopy at 3 years.</strong></p>\n<p><strong>Colorectal polyp</strong> is the term used for any <strong>protrusion</strong> of the <strong>mucosa </strong>of the colon and rectum. It encompasses a variety of <strong>histologically different tumours</strong> (like inflammatory polyps, hamartomatous polyps, serrated polyps, adenomas and malignant polyps). Polyps can occur singly, synchronously in small numbers or as part of a polyposis syndrome. </p>\n<p><strong>Metaplastic or hyperplastic polyps</strong> are common and are <strong>generally</strong> considered <strong>benign</strong>. Sessile serrated lesions and hyperplastic polyps ≥10 mm may lead to dysplasia and malignancy along what is termed as the ‘serrated pathway’. Such polyps should be <strong>removed</strong> and a <strong>follow-up colonoscopy</strong> should be arranged.</p>\n<p>Based on the histological findings upon excision, follow-up is done as below:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Biopsy findings</strong></td>\n<td> </td>\n<td><strong>Follow-up protocol</strong></td>\n</tr>\n<tr>\n<td>Colo rectal cancer</td>\n<td> </td>\n<td>A colonoscopy is done every year</td>\n</tr>\n<tr>\n<td><strong>&gt;20mm sessile polyp-</strong></td>\n<td><strong>-if completely resected</strong></td>\n<td><strong>One-off Followup Colonoscopy after 3 years</strong></td>\n</tr>\n<tr>\n<td> </td>\n<td>-if residual disease present</td>\n<td>Site check at 2-6 months, yearly colonoscopy thereafter</td>\n</tr>\n<tr>\n<td>High-risk polyp and </td>\n<td> </td>\n<td>One-off Follow-up Colonoscopy after 3 years</td>\n</tr>\n<tr>\n<td>Low-risk polyp</td>\n<td> </td>\n<td>No specific follow-up</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Thus in this patient follow-up colonoscopy after three years should be advised to look for recurrence.</p><hr><h3>Related Pearl: Classification of colorectal polyps</h3><p>Colorectal polyps can be classified as:</p>\n<p><strong>Neoplastic </strong></p>\n<p>Adenomatous polyps:</p>\n<ul>\n<li>Tubular adenoma (Most common)</li>\n<li>Tubulovillous adenomas</li>\n<li>Villous adenoma (highest risk of malignancy)</li>\n</ul>\n<p><strong>Non-neoplastic: </strong></p>\n<ul>\n<li>Hyperplastic</li>\n<li>Hamartomatous\n<ul>\n<li>Juvenile polyp(solitary)-benign</li>\n<li>Juvenile polyposis syndromes (multiple)-premalignant</li>\n<li>Peutz-Jeghers syndrome- occasionally carcinoma may develop.</li>\n<li>Cronkite-Canada syndrome*</li>\n</ul>\n</li>\n<li>Inflammatory\n<ul>\n<li>Pseudopolyp</li>\n<li>Benign lymphoid polyp</li>\n</ul>\n</li>\n</ul>\n<p>Note:</p>\n<p>*Cronkite-Canada syndrome: Cancer occurs in the stomach, colon, and rectum, but it remains controversial whether these polyps&nbsp; possess malignant potential. As many as 15% of patients with Cronkite- Canada syndrome have a malignant tumor at the time of diagnosis</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF9837",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is a false statement regarding liver transplantation (LT)?",
      "choices": [
        {
          "id": 1,
          "text": "The ideal graft weight to recipient weight ratio (GRWR) in living donor transplant is >0.8 %."
        },
        {
          "id": 2,
          "text": "In domino LT, liver grafts with metabolic diseases is used as they are structurally and functionally normal."
        },
        {
          "id": 3,
          "text": "Extended criteria donors and paired-exchange LT decrease waitlist mortality."
        },
        {
          "id": 4,
          "text": "Reduced size LT involves dividing the whole liver into right lobe for an adult patient and left lateral segments for pediatric patients."
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The false statement regarding liver transplantation is <strong>option D</strong>. <strong>Reduced-size liver transplantation</strong> involves the <strong>resection</strong> of a <strong>full-size liver</strong> to appropriately fit in the abdominal cavity of small adults/adolescents. It is reserved only for <strong>urgent transplantation</strong>.&nbsp;On the contrary, <strong>split LT</strong> involves <strong>dividing</strong> the whole donor liver into a <strong>left lateral segment</strong> (segments II and III) for a <strong>pediatric</strong> patient and a <strong>right lobe</strong> (segments I, IV-VIII) for an <strong>adult</strong> patient.</p>\n<p>Option A: The required graft volume in a living donor transplant is measured by graft weight to recipient weight ratio <strong>(GRWR)</strong> or ratio of graft volume <strong>(GV)</strong> to recipient standard liver volume<strong> (SLV)</strong>. The ideal<strong> GRWR</strong> is <strong>&gt;0.8 %</strong> or <strong>GV/SLV</strong> is <strong>&gt; 35%</strong>. The <strong>remnant</strong> donor liver mass is kept at <strong>&gt;30%</strong> for safe regeneration.</p>\n<p>Option B: <strong>Domino liver transplant</strong> involves transplanting a liver from a<strong> donor with metabolic disease</strong> (eg: familial amyloid polyneuropathy) to a <strong>recipient with end-stage liver disease</strong> (eg: hepatocellular carcinoma). The donor also receives an LT (healthy donor) and is prioritized over the end-stage liver disease recipient. As a liver with metabolic diseases is structurally and functionally normal, it can prolong the recipient&rsquo;s life by at least 15-20 years as they will not develop the metabolic disease immediately.</p>\n<p>Option C: <strong>Extended criteria donors/ECDs</strong> (liver grafts extracted from donors after circulatory death) and <strong>paired-exchange technique</strong> are used to <strong>decrease waitlist mortality</strong>. However, ECDs have poor graft function due to prolonged hypoxia and are associated with higher infection transmission and biliary complications.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF7911",
      "difficulty": "hard"
    }
  ]
}